Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria.

Autor: Cihanbeylerden M; Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Teixeira J; Department of Dermatology and Venereology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal., Kayıkçı H; Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Tüccar Ç; Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Kalyoncu AF; Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Damadoglu E; Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Gonçalo M; Department of Dermatology and Venereology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal.; Faculty of Medicine, University of Coimbra, Coimbra, Portugal., Karakaya G; Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Allergy [Allergy] 2024 Dec 26. Date of Electronic Publication: 2024 Dec 26.
DOI: 10.1111/all.16458
Databáze: MEDLINE